Julian J.K. Lohmeyer

SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia

Constanze Schneider, Thomas Oellerich, Hanna‐Mari Baldauf et al. · Nature Medicine · 2016 · 166 citations

Hematological Malignancy, Medicine, Acute Myeloid Leukemia +8

An mRNA SARS-CoV-2 Vaccine Employing Charge-Altering Releasable Transporters with a TLR-9 Agonist Induces Neutralizing Antibodies and T Cell Memory

Ole Audun Werner Haabeth, Julian J.K. Lohmeyer, Adrienne Sallets et al. · ACS Central Science · 2021 · 65 citations · Full text

CD20-Targeted Therapy Ablates <i>De Novo</i> Antibody Response to Vaccination but Spares Preestablished Immunity

Tanaya Shree, Vishnu Shankar, Julian J.K. Lohmeyer et al. · Blood Cancer Discovery · 2022 · 47 citations · Full text

Intratumoral immunotherapy relies on B and T cell collaboration

Idit Sagiv-Barfi, Debra K. Czerwinski, Tanaya Shree et al. · Science Immunology · 2022 · 37 citations · Full text

Tumor Immunology, Combinatorial Approach, Cancer Immunosurveillance +14

An mRNA SARS-CoV-2 vaccine employing Charge-Altering Releasable Transporters with a TLR-9 agonist induces neutralizing antibodies and T cell memory

Ole Audun Werner Haabeth, Julian J.K. Lohmeyer, Adrienne Sallets et al. · 2021 · 11 citations · Full text